v3.26.1
Segment Reporting
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting

14. Segment Reporting

 

The Company’s only segment is Clinical Stage Biotechnology. The CODM reviews profit and loss information on a consolidated basis in order to assess performance and make decisions about the allocation of operating and capital resources.

 

The following table presents disaggregated financial information with respect to the Company’s Clinical Stage Biotechnology segment for the three months ended March 31, 2026 and 2025, respectively:

 

   2026   2025 
   For the Three Months Ended 
   March 31, 
   2026   2025 
         
Grant Revenue  $-   $278,628 
Operating Expenses:          
Research and development          
Clinical trial and research expenses   189,138    250,496 
Insurance   39,663    47,989 
Payroll and taxes   78,017    82,179 
Stock based compensation   13,342    13,894 
Rent and utilities   9,064    8,146 
Travel and entertainment   4,110    - 
Total research and development   333,334    402,704 
General and administrative          
Depreciation   466    466 
Directors fees   77,500    77,500 
Donations   -    50,000 
Insurance   35,305    26,760 
Legal fees   143,351    121,022 
Other general and administrative expenses   27,631    16,872 
Payroll and taxes   221,673    216,713 
Professional fees   109,955    158,627 
Rent and utilities   5,294    4,651 
Stock based compensation   292,709    301,206 
Travel and entertainment   685    - 
Foreign currency transaction losses   -    48 
Total general and administrative   914,569    973,865 
Total Operating Loss   (1,247,903)   (1,097,941)
Other Expense:          
Interest expense   (53,046)   (63,661)
Net Loss  $(1,300,949)  $(1,161,602)

 

Other general and administrative expenses primarily include costs associated with office expenses, bank charges, computer-related expenses, dues and subscriptions, and taxes. These expenses are incurred as part of the day-to-day operations and general administration of the Company’s segment.